Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 213

1.

D-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis.

Jara-Palomares L, Solier-Lopez A, Elias-Hernandez T, Asensio-Cruz MI, Blasco-Esquivias I, Sanchez-Lopez V, de la Borbolla MR, Arellano-Orden E, Suarez-Valdivia L, Marin-Romero S, Marin-Barrera L, Ruiz-Garcia A, Montero-Romero E, Navarro-Herrero S, Lopez-Campos JL, Serrano-Gotarredona MP, Praena-Fernandez JM, Sanchez-Diaz JM, Otero-Candelera R.

Br J Cancer. 2018 Oct 15. doi: 10.1038/s41416-018-0269-5. [Epub ahead of print]

PMID:
30318508
2.

Determinants of medical prescriptions for COPD care: an analysis of the EPOCONSUL clinical audit.

Lopez-Campos JL, Navarrete BA, Soriano JB, Soler-Cataluña JJ, González-Moro JMR, Ferrer MEF, Rubio MC.

Int J Chron Obstruct Pulmon Dis. 2018 Jul 27;13:2279-2288. doi: 10.2147/COPD.S160842. eCollection 2018.

3.

Alpha-1 antitrypsin deficiency: outstanding questions and future directions.

Torres-Durán M, Lopez-Campos JL, Barrecheguren M, Miravitlles M, Martinez-Delgado B, Castillo S, Escribano A, Baloira A, Navarro-Garcia MM, Pellicer D, Bañuls L, Magallón M, Casas F, Dasí F.

Orphanet J Rare Dis. 2018 Jul 11;13(1):114. doi: 10.1186/s13023-018-0856-9. Review.

4.

Community Assessment of COPD Health Care (COACH) study: a clinical audit on primary care performance variability in COPD care.

Abad-Arranz M, Moran-Rodríguez A, Mascarós Balaguer E, Quintana Velasco C, Abad Polo L, Núñez Palomo S, Gonzálvez Rey J, Fernández Vargas AM, Hidalgo Requena A, Helguera Quevedo JM, García Pardo M, Lopez-Campos JL; COACH study investigators.

BMC Med Res Methodol. 2018 Jul 3;18(1):68. doi: 10.1186/s12874-018-0528-4.

5.

Testing for alpha-1 antitrypsin in COPD in outpatient respiratory clinics in Spain: A multilevel, cross-sectional analysis of the EPOCONSUL study.

Calle Rubio M, Soriano JB, López-Campos JL, Soler-Cataluña JJ, Alcázar Navarrete B, Rodríguez González-Moro JM, Miravitlles M, Barrecheguren M, Fuentes Ferrer ME, Rodriguez Hermosa JL; EPOCONSUL Study.

PLoS One. 2018 Jun 28;13(6):e0198777. doi: 10.1371/journal.pone.0198777. eCollection 2018.

6.

Current controversies in the stepping up and stepping down of inhaled therapies for COPD at the patient level.

Lopez-Campos JL, Carrasco Hernández L, Muñoz X, Bustamante V, Barreiro E.

Respirology. 2018 Jun 20. doi: 10.1111/resp.13341. [Epub ahead of print] Review.

7.
8.

Characteristics of COPD Patients Managed in Respiratory Medicine Departments in Spain, According to GOLD Groups and GesEPOC Clinical Phenotypes.

Izquierdo JL, Miravitlles M, Esquinas C, Pérez M, Calle M, López Campos JL, Rodríguez González-Moro JM, Casanova C, Esteban C, de Lucas P.

Arch Bronconeumol. 2018 May 28. pii: S0300-2896(18)30176-5. doi: 10.1016/j.arbres.2018.03.021. [Epub ahead of print] English, Spanish.

9.

The Expression of AQP1 IS Modified in Lung of Patients With Idiopathic Pulmonary Fibrosis: Addressing a Possible New Target.

Galán-Cobo A, Arellano-Orden E, Sánchez Silva R, López-Campos JL, Gutiérrez Rivera C, Gómez Izquierdo L, Suárez-Luna N, Molina-Molina M, Rodríguez Portal JA, Echevarría M.

Front Mol Biosci. 2018 May 3;5:43. doi: 10.3389/fmolb.2018.00043. eCollection 2018.

10.

Reliability and usefulness of spirometry performed during admission for COPD exacerbation.

Fernández-Villar A, Represas-Represas C, Mouronte-Roibás C, Ramos-Hernández C, Priegue-Carrera A, Fernández-García S, López-Campos JL.

PLoS One. 2018 Mar 26;13(3):e0194983. doi: 10.1371/journal.pone.0194983. eCollection 2018.

11.

Current Approaches for Phenotyping as a Target for Precision Medicine in COPD Management.

Lopez-Campos JL, Centanni S.

COPD. 2018 Apr;15(2):108-117. doi: 10.1080/15412555.2018.1443064. Epub 2018 Mar 20.

PMID:
29558165
12.

Research highlights from the 2017 ERS International Congress: airway diseases in focus.

Andersson C, Bonvini SJ, Horvath P, Marquez E, Satia I, Kirkham P, Schleich F, Idzko M, Gosens R, Lopez-Campos JL, Bossios A, Usmani O, Spanevello A, Adcock IM, Mathioudakis AG.

ERJ Open Res. 2018 Mar 13;4(1). pii: 00163-2017. doi: 10.1183/23120541.00163-2017. eCollection 2018 Jan. Review.

13.

Mixed Th2 and non-Th2 inflammatory pattern in the asthma-COPD overlap: a network approach.

de Llano LP, Cosío BG, Iglesias A, de Las Cuevas N, Soler-Cataluña JJ, Izquierdo JL, López-Campos JL, Calero C, Plaza V, Miravitlles M, Torrego A, Martinez-Moragon E, Soriano JB, Viña AL, Bobolea I.

Int J Chron Obstruct Pulmon Dis. 2018 Feb 12;13:591-601. doi: 10.2147/COPD.S153694. eCollection 2018.

14.

Changes and Clinical Consequences of Smoking Cessation in Patients With COPD: A Prospective Analysis From the CHAIN Cohort.

Martínez-González C, Casanova C, de-Torres JP, Marín JM, de Lucas P, Fuster A, Cosío BG, Calle M, Peces-Barba G, Solanes I, Agüero R, Feu-Collado N, Alfageme I, Romero Plaza A, Balcells E, de Diego A, Marín Royo M, Moreno A, Llunell Casanovas A, Galdiz JB, Golpe R, Lacárcel Bautista C, Cabrera C, Marin A, Soriano JB, Lopez-Campos JL; CHAIN Study Investigators.

Chest. 2018 Aug;154(2):274-285. doi: 10.1016/j.chest.2018.02.007. Epub 2018 Feb 22.

PMID:
29476876
15.

The post-truth behind the asthma-COPD overlap and the orbit of Mercury: lessons from the CHACOS study.

Pérez de Llano L, López-Campos JL, Cosío BG.

Arch Bronconeumol. 2018 Apr;54(4):175-176. doi: 10.1016/j.arbres.2018.01.004. Epub 2018 Feb 17. English, Spanish. No abstract available.

16.

Cardiovascular Studies in Patients with Chronic Obstructive Pulmonary Disease Due to Biomass Smoke or Tobacco.

Golpe R, Sanjuán-López P, Martín-Robles I, González-Juanatey C, Pérez-de-Llano L, López-Campos JL.

Lung. 2018 Apr;196(2):195-200. doi: 10.1007/s00408-018-0095-9. Epub 2018 Feb 12.

PMID:
29435736
17.

Predictors of one-year mortality after hospitalization for an exacerbation of COPD.

Esteban C, Castro-Acosta A, Alvarez-Martínez CJ, Capelastegui A, López-Campos JL, Pozo-Rodriguez F.

BMC Pulm Med. 2018 Jan 25;18(1):18. doi: 10.1186/s12890-018-0574-z.

18.

Medical Care According to Risk Level and Adaptation to Spanish COPD Guidelines (Gesepoc): The Epoconsul Study.

Calle Rubio M, Rodríguez Hermosa JL, Soler-Cataluña JJ, López-Campos JL, Alcazar Navarrete B, Soriano JB, Rodríguez Gónzalez-Moro JM, Fuentes Ferrer ME, Miravitlles M; y el Grupo Epoconsul.

Arch Bronconeumol. 2018 May;54(5):270-279. doi: 10.1016/j.arbres.2017.11.015. Epub 2018 Feb 1. English, Spanish.

19.

Understanding of COPD among final-year medical students.

Mohigefer J, Calero-Acuña C, Marquez-Martin E, Ortega-Ruiz F, Lopez-Campos JL.

Int J Chron Obstruct Pulmon Dis. 2017 Dec 28;13:131-139. doi: 10.2147/COPD.S138539. eCollection 2018.

20.

Characterization of Novel Missense Variants of SERPINA1 Gene Causing Alpha-1 Antitrypsin Deficiency.

Matamala N, Lara B, Gomez-Mariano G, Martínez S, Retana D, Fernandez T, Silvestre RA, Belmonte I, Rodriguez-Frias F, Vilar M, Sáez R, Iturbe I, Castillo S, Molina-Molina M, Texido A, Tirado-Conde G, Lopez-Campos JL, Posada M, Blanco I, Janciauskiene S, Martinez-Delgado B.

Am J Respir Cell Mol Biol. 2018 Jun;58(6):706-716. doi: 10.1165/rcmb.2017-0179OC.

PMID:
29232161
21.

Variability in adherence to clinical practice guidelines and recommendations in COPD outpatients: a multi-level, cross-sectional analysis of the EPOCONSUL study.

Calle Rubio M, López-Campos JL, Soler-Cataluña JJ, Alcázar Navarrete B, Soriano JB, Rodríguez González-Moro JM, Fuentes Ferrer ME, Rodríguez Hermosa JL; EPOCONSUL Study.

Respir Res. 2017 Dec 2;18(1):200. doi: 10.1186/s12931-017-0685-8.

22.

Redefining Cut-Points for High Symptom Burden of the Global Initiative for Chronic Obstructive Lung Disease Classification in 18,577 Patients With Chronic Obstructive Pulmonary Disease.

Smid DE, Franssen FME, Gonik M, Miravitlles M, Casanova C, Cosio BG, de Lucas-Ramos P, Marin JM, Martinez C, Mir I, Soriano JB, de Torres JP, Agusti A, Atalay NB, Billington J, Boutou AK, Brighenti-Zogg S, Chaplin E, Coster S, Dodd JW, Dürr S, Fernandez-Villar A, Groenen MTJ, Guimarães M, Hejduk K, Higgins V, Hopkinson NS, Horita N, Houben-Wilke S, Janssen DJA, Jehn M, Joerres R, Karch A, Kelly JL, Kim YI, Kimura H, Koblizek V, Kocks JH, Kon SSC, Kwon N, Ladeira I, Lee SD, Leuppi JD, Locantore N, Lopez-Campos JL, D-C Man W, Maricic L, Mendoza L, Miedinger D, Mihaltan F, Minami S, van der Molen T, Murrells TJ, Nakken N, Nishijima Y, Norman IJ, Novotna B, O'Donnell DE, Ogata Y, Pereira ED, Piercy J, Price D, Pothirat C, Raghavan N, Ringbaek T, Sajkov D, Sigari N, Singh S, Small M, da Silva GF, Tanner RJ, Tsiligianni IG, Tulek B, Tzanakis N, Vanfleteren LEGW, Watz H, Webb KA, Wouters EFM, Xie GG, Yoshikawa M, Spruit MA.

J Am Med Dir Assoc. 2017 Dec 1;18(12):1097.e11-1097.e24. doi: 10.1016/j.jamda.2017.09.003. Review.

PMID:
29169740
23.

Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD.

Casanova C, Celli BR, de-Torres JP, Martínez-Gonzalez C, Cosio BG, Pinto-Plata V, de Lucas-Ramos P, Divo M, Fuster A, Peces-Barba G, Calle-Rubio M, Solanes I, Aguero R, Feu-Collado N, Alfageme I, De Diego A, Romero A, Balcells E, Llunell A, Galdiz JB, Marin M, Moreno A, Cabrera C, Golpe R, Lacarcel C, Soriano JB, López-Campos JL, Soler-Cataluña JJ, Marin JM.

Eur Respir J. 2017 Nov 22;50(5). pii: 1701162. doi: 10.1183/13993003.01162-2017. Print 2017 Nov.

PMID:
29167301
24.

Differences in systemic inflammation between cigarette and biomass smoke-induced COPD.

Golpe R, Martín-Robles I, Sanjuán-López P, Pérez-de-Llano L, González-Juanatey C, López-Campos JL, Arellano-Orden E.

Int J Chron Obstruct Pulmon Dis. 2017 Sep 1;12:2639-2646. doi: 10.2147/COPD.S141068. eCollection 2017.

25.

The variability of respiratory symptoms and associated factors in COPD.

Miravitlles M, Izquierdo JL, Esquinas C, Pérez M, Calle M, López-Campos JL, Rodríguez González-Moro JM, Casanova C, Esteban C, de Lucas P.

Respir Med. 2017 Aug;129:165-172. doi: 10.1016/j.rmed.2017.06.017. Epub 2017 Jun 26.

PMID:
28732827
26.

Treatment of COPD Exacerbation in Switzerland: Results and Recommendations of the European COPD Audit.

Buess M, Schilter D, Schneider T, Maurer M, Borer H, Thurnheer R, Köhler E, Junker L, Jahn K, Grob M, Rüdiger J, Geiser T, Helfenstein E, Solèr M, Fiechter R, Sigrist T, Brun P, Barandun J, Koltai E, López-Campos JL, Hartl S, Roberts M, Schumann DM, Tamm M, Stolz D.

Respiration. 2017;94(4):355-365. doi: 10.1159/000477911. Epub 2017 Jul 19.

27.

Double bronchodilation in chronic obstructive pulmonary disease: a crude analysis from a systematic review.

Lopez-Campos JL, Calero-Acuña C, Márquez-Martín E, Quintana Gallego E, Carrasco-Hernández L, Abad Arranz M, Ortega Ruiz F.

Int J Chron Obstruct Pulmon Dis. 2017 Jun 23;12:1867-1876. doi: 10.2147/COPD.S132962. eCollection 2017. Review.

28.

Accuracy of COPD Diagnosis During an Admission: The European Perspective.

Lopez-Campos JL, Castro-Acosta A, Pozo-Rodriguez F, Hartl S, Roberts CM.

Chest. 2017 Jun;151(6):1396-1397. doi: 10.1016/j.chest.2017.01.044. No abstract available.

PMID:
28599931
29.

Home mechanical ventilation for stable COPD in GOLD 2017: What are we ventilating?

Lopez-Campos JL, Caballero-Eraso C, Barrot-Cortés E.

Respirology. 2017 Nov;22(8):1497-1499. doi: 10.1111/resp.13091. Epub 2017 May 30. No abstract available.

30.

Major Changes in the Spanish COPD Guidelines (GesEPOC) 2017: Crossing Bridges.

Lopez-Campos JL, Marquez-Martín E, Ortega-Ruiz F.

Arch Bronconeumol. 2017 Jun;53(6):291-292. doi: 10.1016/j.arbres.2017.04.006. Epub 2017 May 12. English, Spanish. No abstract available.

31.

Th-2 signature in chronic airway diseases: towards the extinction of asthma-COPD overlap syndrome?

Cosío BG, Pérez de Llano L, Lopez Viña A, Torrego A, Lopez-Campos JL, Soriano JB, Martinez Moragon E, Izquierdo JL, Bobolea I, Callejas J, Plaza V, Miravitlles M, Soler-Catalunya JJ; on behalf of the CHACOS study group.

Eur Respir J. 2017 May 1;49(5). pii: 1602397. doi: 10.1183/13993003.02397-2016. Print 2017 May.

PMID:
28461299
32.

Seasonal variability in clinical care of COPD outpatients: results from the Andalusian COPD audit.

López-Campos JL, Abad Arranz M, Calero-Acuña C, Romero-Valero F, Ayerbe-García R, Hidalgo-Molina A, Aguilar-Pérez-Grovas RI, García-Gil F, Casas-Maldonado F, Caballero-Ballesteros L, Sánchez-Palop M, Pérez-Tejero D, Segado Soriano A, Calvo-Bonachera J, Hernández-Sierra B, Doménech A, Arroyo-Varela M, González-Vargas F, Cruz-Rueda JJ.

Int J Chron Obstruct Pulmon Dis. 2017 Mar 3;12:785-792. doi: 10.2147/COPD.S121885. eCollection 2017.

33.

Recent lung cancer mortality trends in Europe: effect of national smoke-free legislation strengthening.

López-Campos JL, Ruiz-Ramos M, Fernandez E, Soriano JB.

Eur J Cancer Prev. 2018 Jul;27(4):296-302. doi: 10.1097/CEJ.0000000000000354.

PMID:
28379885
34.

Overdiagnosis of COPD: precise definitions and proposals for improvement.

Fernández-Villar A, Soriano JB, López-Campos JL.

Br J Gen Pract. 2017 Apr;67(657):183-184. doi: 10.3399/bjgp17X690389. No abstract available.

35.

Triple Therapy vs. Triple Therapy in COPD.

Lopez-Campos JL, Marquez-Martín E, Ortega-Ruiz F.

Arch Bronconeumol. 2017 Aug;53(8):419-420. doi: 10.1016/j.arbres.2017.01.020. Epub 2017 Mar 14. English, Spanish. No abstract available.

36.

The importance of rural living and sex in exposure to biomass smoke.

Lopez-Campos JL, Fernandez Villar A, Casamor R.

Arch Bronconeumol. 2017 May;53(5):290. doi: 10.1016/j.arbres.2017.01.005. Epub 2017 Feb 24. English, Spanish. No abstract available.

37.

Clinical audit of COPD in outpatient respiratory clinics in Spain: the EPOCONSUL study.

Calle Rubio M, Alcázar Navarrete B, Soriano JB, Soler-Cataluña JJ, Rodríguez González-Moro JM, Fuentes Ferrer ME, López-Campos JL.

Int J Chron Obstruct Pulmon Dis. 2017 Jan 25;12:417-426. doi: 10.2147/COPD.S124482. eCollection 2017.

38.

Evaluation of symptomatic patients without airflow obstruction: back to the future.

Lopez-Campos JL, Alcazar B.

J Thorac Dis. 2016 Dec;8(12):E1657-E1660. doi: 10.21037/jtd.2016.12.103. No abstract available.

39.

Specific networks of plasma acute phase reactants are associated with the severity of chronic obstructive pulmonary disease: a case-control study.

Arellano-Orden E, Calero-Acuña C, Cordero JA, Abad-Arranz M, Sánchez-López V, Márquez-Martín E, Ortega-Ruiz F, López-Campos JL.

Int J Med Sci. 2017 Jan 15;14(1):67-74. doi: 10.7150/ijms.16907. eCollection 2017.

40.

Chronic obstructive pulmonar disease: The Hunt for the Right Classification.

Ortega Ruiz F, Márquez Martín E, López-Campos JL.

Arch Bronconeumol. 2017 Mar;53(3):91-92. doi: 10.1016/j.arbres.2016.11.014. Epub 2017 Jan 3. English, Spanish. No abstract available.

41.

How Do Dual Long-Acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease?

Beeh KM, Burgel PR, Franssen FME, Lopez-Campos JL, Loukides S, Hurst JR, Fležar M, Ulrik CS, Di Marco F, Stolz D, Valipour A, Casserly B, Ställberg B, Kostikas K, Wedzicha JA.

Am J Respir Crit Care Med. 2017 Jul 15;196(2):139-149. doi: 10.1164/rccm.201609-1794CI. Review.

42.

Relationships between chronic obstructive pulmonary disease and lung cancer: biological insights.

Barreiro E, Bustamante V, Curull V, Gea J, López-Campos JL, Muñoz X.

J Thorac Dis. 2016 Oct;8(10):E1122-E1135. Review.

43.

Understanding variation in length of hospital stay for COPD exacerbation: European COPD audit.

Ruparel M, López-Campos JL, Castro-Acosta A, Hartl S, Pozo-Rodriguez F, Roberts CM.

ERJ Open Res. 2016 Mar 5;2(1). pii: 00034-2015. eCollection 2016 Jan.

44.

Distribution and Outcomes of a Phenotype-Based Approach to Guide COPD Management: Results from the CHAIN Cohort.

Cosio BG, Soriano JB, López-Campos JL, Calle M, Soler JJ, de-Torres JP, Marín JM, Martínez C, de Lucas P, Mir I, Peces-Barba G, Feu-Collado N, Solanes I, Alfageme I; CHAIN study.

PLoS One. 2016 Sep 29;11(9):e0160770. doi: 10.1371/journal.pone.0160770. eCollection 2016. Erratum in: PLoS One. 2016 Nov 2;11(11):e0166257.

45.

Beta-blockers and COPD: the show must go on.

Lopez-Campos JL, Márquez-Martín E, Casanova C.

Eur Respir J. 2016 Sep;48(3):600-3. doi: 10.1183/13993003.01222-2016. No abstract available.

46.

IL-11 and CCL-1: Novel Protein Diagnostic Biomarkers of Lung Adenocarcinoma in Bronchoalveolar Lavage Fluid (BALF).

Pastor MD, Nogal A, Molina-Pinelo S, Quintanal-Villalonga Á, Meléndez R, Ferrer I, Romero-Romero B, De Miguel MJ, López-Campos JL, Corral J, García-Carboner R, Carnero A, Paz-Ares L.

J Thorac Oncol. 2016 Dec;11(12):2183-2192. doi: 10.1016/j.jtho.2016.07.026. Epub 2016 Aug 12.

47.

Occupational and Biomass Exposure in Chronic Obstructive Pulmonary Disease: Results of a Cross-Sectional Analysis of the On-Sint Study.

López-Campos JL, Fernández-Villar A, Calero-Acuña C, Represas-Represas C, López-Ramírez C, Fernández VL, Casamor R; en nombre de los investigadores del estudio On-Sint.

Arch Bronconeumol. 2017 Jan;53(1):7-12. doi: 10.1016/j.arbres.2016.04.013. Epub 2016 Jul 16. English, Spanish.

48.

Frequent or Persistent Exacerbations: Identifying The Real Problem.

Lopez-Campos JL, Calero-Acuña C, Márquez-Martín E.

Arch Bronconeumol. 2016 Dec;52(12):577-578. doi: 10.1016/j.arbres.2016.05.019. Epub 2016 Jun 30. English, Spanish. No abstract available.

49.

Readmission in COPD patients: should we consider it a marker of quality of care or a marker of a more severe disease with a worse prognosis?

Hartl S, Lopez-Campos JL.

Eur Respir J. 2016 Jul;48(1):281-2. doi: 10.1183/13993003.00885-2016. No abstract available.

50.

Determinants for changing the treatment of COPD: a regression analysis from a clinical audit.

López-Campos JL, Abad Arranz M, Calero Acuña C, Romero Valero F, Ayerbe García R, Hidalgo Molina A, Aguilar Perez-Grovas RI, García Gil F, Casas Maldonado F, Caballero Ballesteros L, Sánchez Palop M, Pérez-Tejero D, Segado A, Calvo Bonachera J, Hernández Sierra B, Doménech A, Arroyo Varela M, González Vargas F, Cruz Rueda JJ.

Int J Chron Obstruct Pulmon Dis. 2016 Jun 2;11:1171-8. doi: 10.2147/COPD.S103614. eCollection 2016.

Supplemental Content

Loading ...
Support Center